Hepatitis Therapeutics Market Major Key Players, Insights, Business Strategies, Growth And Forecast 2033

The hepatitis therapeutics market size has grown steadily in recent years. It will grow from $18.35 billion in 2023 to $18.89 billion in 2024 at a compound annual growth rate (CAGR) of 3.0%. The growth in the historic period can be attributed to vaccine development, antiviral medications, public health initiatives, research funding, emerging therapies.

The hepatitis therapeutics market size is expected to see steady growth in the next few years. It will grow to $21.79 billion in 2028 at a compound annual growth rate (CAGR) of 3.6%. The growth in the forecast period can be attributed to continued research and development, global health efforts, shift in patient care, government initiatives, rising disease awareness. Major trends in the forecast period include patient advocacy and support, continuous monitoring and follow-up, healthcare equity, telemedicine and remote care, focus on hepatitis c elimination.

Market Overview -
Hepatitis is an inflammation of the liver caused by several viruses and non-viruses. The term hepatitis therapeutics describes the drugs that are used to treat all forms of hepatitis. The two drugs used to treat hepatitis are immune modulators and oral antivirals.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=9956&type=smp

Global Surge In Hepatitis Infections Drives Growth In The Hepatitis Therapeutic Market
The rise in hepatitis infection globally is expected to propel the growth of the hepatitis therapeutic market going forward. The rise in hepatitis infection is due to inadequate access to healthcare and vaccinations, an increase in intravenous drug use, unsafe blood transfusion practices, and poor sanitation and hygiene conditions in some parts of the world. For instance, in April 2022, according to World Health Organization (WHO), a US-based united nations public health agency, from 11 nations, at least 169 cases of acute hepatitis of unknown origin have been documented and 350 million individuals worldwide have viral hepatitis B or C, yet for the majority, testing, and treatment are still out of reach. Therefore, the market for hepatitis therapeutics is expanding due to the rise in hepatitis infection.

Competitive Landscape -
Major companies operating in the hepatitis therapeutics market report are Gilead Sciences Inc., Bristol-Myers Squibb Co., AbbVie Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Cipla Inc., F Hoffmann-La Roche Ltd., Biocon Limited, LAURUS Labs Ltd., Zydus Lifesciences Limited, Hetero Healthcare Limited, Novartis AG, Sanofi SA, GlaxoSmithKline plc, Lupin Ltd., Teva Pharmaceutical Industries Ltd., NATCO Pharma Limited, Mylan NV, Pfizer Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Biocon Biopharmaceuticals Pvt. Ltd., Zealand Pharma A/S, Zenyaku Kogyo Co. Ltd., Zosano Pharma Corporation .

Advancing Hepatitis Therapeutics: Recent Innovations And Fda Approval Of Vemlidy By Gilead Sciences, Inc
Product innovations have emerged as the key trend gaining popularity in the hepatitis therapeutics market. Major companies operating in the hepatitis therapeutics market are developing new products to sustain their position in the market. For instance, in November 2022, Gilead Sciences, Inc., a US-based biopharmaceutical company received approval from FDA for a medicine called Vemlidy (tenofovir alafenamide) for the treatment of paediatric patients with chronic hepatitis B virus infection. Vemlidy is a targeted prodrug of tenofovir that received FDA approval in 2016 as a once-daily treatment for individuals with chronic hepatitis B virus (HBV) infection and compensated liver disease. According to recommendations from the American Liver Foundation, it is a preferred or first-line treatment for persons with chronic HBV and compensated liver disease.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/hepatitis-therapeutics-global-market-report

Key Segments -
The hepatitis therapeutics market covered in this report is segmented -
1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types
2) By Drug Class: Oral Antivirals, Immune Modulators
3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.